CellSource Co., Ltd. (JP:4880) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CellSource Co., Ltd. experienced a significant shortfall in its fiscal year results compared to earlier forecasts due to challenges in implementing synovium-derived stem cell services. The company reported a 69.3% drop in operating profit, leading to a downward revision in earnings expectations. Despite the setback, CellSource will continue its collaboration with medical institutions to develop these services.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.